The SEC apparently still loves LabCorp

EQUITY ALERT: Rosen Law Firm Announces Investigation of LipoScience, Inc. Concerning its Proposed Sale to LabCorp – LPDX

September 25, 2014 06:02 PM Eastern Daylight Time

NEW YORK–BUSINESS WIRE–The Rosen Law Firm, P.A. announces that it is investigating the Board of Directors of LipoScience, Inc. NASDAQ:LPDX for possible breaches of fiduciary duty and other violations of law by failing to adequately shop LipoScience to maximize shareholder value before agreeing to be acquired by Laboratory Corporation of America Holdings NYSE: LH.

If you would like to join the action, go to or contact Phillip Kim or Kevin Chan, toll-free at 866-767-3653, or via e-mail at or There is no cost or obligation to you.

Under the terms of the proposed transaction, shareholders will receive $5.25 in cash for each share of LipoScience they own. The proposed transaction is valued at approximately $85.3 million. The investigation relates to whether the proposal for $5.25 in cash per share is fair to public shareholders and whether LipoScience’s Board breached its fiduciary duties in connection with the proposed sale.

If you currently own shares of LipoScience and wish to obtain additional information, please visit the website at You may also contact Phillip Kim or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at or

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.


The Rosen Law Firm P.A.

Phillip Kim, Esq.

Kevin Chan, Esq.

Laurence Rosen, Esq.

275 Madison Avenue 34th Floor

New York, New York 10016

Tel: 212 686-1060

Toll Free: 1-866-767-3653

Fax: 212 202-3827

via EQUITY ALERT: Rosen Law Firm Announces Investigation of LipoScience, Inc. Concerning its Proposed Sale to LabCorp – LPDX | Business Wire.


That the SEC is still allowing LabCorp to make acquisitions is no surprise. That it is allowing LabCorp to acquire a company that may some some ethical issues is no surprise, either (see previous posts about LabCorp’s acquisition of Orchid Cellmark).

The only surprises in store are for former LipoScience shareholders when the acquisition is approved, i.e.; the frequent lawsuits involving LabCorp, its officers selling startling numbers of their shares, their announcements of  accounting gymnastics, etc.

Our federal regulatory agencies aren’t just a disappointment. They’re a disgrace. And a menace.

About Susan Chandler

Now-disabled interior/exterior designer dragged into battling conviction corruption from its periphery in a third personal battle with civil public corruption.
This entry was posted in Uncategorized and tagged , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.